PORTSMOUTH, NH-- Salient Surgical Technologies, Inc., a privately held medical technology company that develops and markets advanced energy devices for use in surgical procedures, today announced the completion of its Series G financing totaling $15.1 million. Investors in the round included Apothecary Capital/BBT Fund, L.P., Arnerich Massena & Associates, Affinity Capital, Medtronic, Inc., and other financial and strategic investors.
Salient will use the proceeds to expand its sales and marketing organization, build upon its health outcomes data and accelerate development of new advanced energy products based on its proprietary Transcollation? technology.
“We are pleased to welcome new investors Apothecary and Affinity, and thank our returning investors for their continued support. We made excellent progress in 2009 and this financing will provide the capital to fund our global expansion and product pipeline on our way to becoming Standard of Care,” stated Joseph F. Army, President and CEO of Salient.
“Apothecary Capital on behalf of the BBT Fund is excited to have the opportunity to invest in Salient Surgical. We look forward to supporting Salient’s compelling technology and its bright future,” stated Alan Sebulsky, Apothecary’s Managing Partner.
About Salient Surgical
Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient’s proprietary Transcollation? technology allows surgeons to rapidly treat tissue at the surgical site by transforming specific types of collagen based structures to improve patient outcomes. Salient’s products are currently used in orthopedic reconstruction, spine and surgical oncology. To date, Transcollation? technology has been used in over 375,000 surgical procedures.
Contact:
Salient Surgical Technologies, Inc. Investors: Rick Altieri (603) 742-1515 Email Contact
